I am more excited about Cholesterol reduction program.
Concerning cardiovascular treatments, a new alternative to statin drugs, which is taken orally as a small pill, provides one of the largest drug opportunities in the world. Lipitor®, which is owned by Pfizer, is the best-selling drug of all time having generated more than US$160B in sales since its launch in 1997. Although now off-patent, it still generates annual sales of around US$2B for Pfizer.
Nyrada is developing a small molecule PCSK9i inhibitor as a single pill to treat people with high levels of cholesterol. Nyrada’s differs from current PCSK9 inhibitors because, being a small molecule drug, means that it can be taken orally. Further, it can be combined with a statin as a single pill treatment to lower cholesterol. Nyrada firmly believes that there is a big market for small molecule PCSK9 inhibitors.
What could this be worth to Pfizer for example!
Regain the dominance in the Cholesterol market!
Food for thought!
Cheers
NYR Price at posting:
22.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)